Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FREDERICK AST

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1699742288
CMS profile
167212
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,329.22

198 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,309.53 197
Education $19.69 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 198 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FREDERICK AST

NPI 1699742288 · CMS profile ID 167212

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 198 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699742288?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FREDERICK AST, NPI 1699742288, CMS profile ID 167212. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 198 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699742288?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FREDERICK AST, NPI 1699742288, CMS profile ID 167212. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 198 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699742288?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FREDERICK AST, NPI 1699742288, CMS profile ID 167212, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 198 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699742288?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

198 matching records · $3,329.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 198 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 198.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $19.2906/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819101479 CMS
AbbVie Inc. $12.3306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793931963 CMS
PFIZER INC. $7.6006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832593353 CMS
GlaxoSmithKline, LLC. $24.4106/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803055521 CMS
GlaxoSmithKline, LLC. $24.7506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803169909 CMS
Amgen Inc. $19.3606/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825318985 CMS
AbbVie Inc. $3.6405/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793931955 CMS
AbbVie Inc. $18.4905/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793931959 CMS
Amgen Inc. $22.5305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825319021 CMS
GlaxoSmithKline, LLC. $1.9105/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802074673 CMS
GlaxoSmithKline, LLC. $19.8605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802499009 CMS
Amgen Inc. $27.2605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825319025 CMS
Lilly USA, LLC $27.4905/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819164683 CMS
GlaxoSmithKline, LLC. $34.9305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803057751 CMS
Janssen Biotech, Inc. $12.5105/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788576381 CMS
AbbVie Inc. $12.2005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793931951 CMS
PFIZER INC. $25.9305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832602735 CMS
Amgen Inc. $17.9105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825318969 CMS
Horizon Therapeutics plc $9.4705/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797067851 CMS
Amgen Inc. $20.4705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825318981 CMS
GlaxoSmithKline, LLC. $24.5605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802440091 CMS
GlaxoSmithKline, LLC. $21.5505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803199797 CMS
Horizon Therapeutics plc $8.8905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797067847 CMS
Collegium Pharmaceutical, Inc. $4.6704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789398045 CMS
Collegium Pharmaceutical, Inc. $15.1604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789398039 CMS
Amgen Inc. $23.2704/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825319017 CMS
BioCryst US Sales Co., LLC $17.9004/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849109847 CMS
Novartis Pharmaceuticals Corporation $21.7704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812593477 CMS
Mallinckrodt Hospital Products Inc. $18.8904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845344823 CMS
Mallinckrodt Hospital Products Inc. $2.8504/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845344821 CMS
GENZYME CORPORATION $21.2904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843444543 CMS
Horizon Therapeutics plc $7.3504/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797067841 CMS
GlaxoSmithKline, LLC. $18.2204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802992499 CMS
GlaxoSmithKline, LLC. $16.7404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803208577 CMS
Mallinckrodt Hospital Products Inc. $20.0604/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845344819 CMS
Mallinckrodt Hospital Products Inc. $2.4004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845344817 CMS
PFIZER INC. $29.9204/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832550643 CMS
Horizon Therapeutics plc $9.0204/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797067837 CMS
AstraZeneca Pharmaceuticals LP $21.5404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829427555 CMS
AstraZeneca Pharmaceuticals LP $16.7904/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829786787 CMS
GlaxoSmithKline, LLC. $31.6204/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802798215 CMS
GlaxoSmithKline, LLC. $22.6304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803123887 CMS
Amgen Inc. $22.7004/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825318977 CMS
AbbVie Inc. $17.5003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793931947 CMS
Lilly USA, LLC $20.3903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819164679 CMS
GlaxoSmithKline, LLC. $14.5303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802410155 CMS
GlaxoSmithKline, LLC. $14.8303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803202877 CMS
Horizon Therapeutics plc $9.4603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797067833 CMS
Amgen Inc. $26.7903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825319009 CMS
Mallinckrodt Hospital Products Inc. $2.5103/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845344813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,691.47 217
PY2020 $3,120.31 180
PY2021 $3,329.22 198
PY2022 $2,968.42 195
PY2023 $2,540.55 162
PY2024 $1,924.51 113
PY2025 $2,986.10 142

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $417,754.79 35
PY2024 Principal investigator $408,139.70 72
PY2023 Principal investigator $34,891.09 8
PY2022 Principal investigator $128,951.30 21
PY2021 Principal investigator $90,942.87 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $38,048.00 12/24/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573059
Principal investigator 1 Janssen Research & Development, LLC $21,460.00 11/10/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175436296
Principal investigator 1 Incyte Corporation $1,800.00 10/30/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577409
Principal investigator 1 Incyte Corporation $500.00 10/30/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577421
Principal investigator 1 Genentech, Inc. $43,144.00 10/15/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573055
Principal investigator 1 AstraZeneca Pharmaceuticals LP $930.73 10/10/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185541702
Principal investigator 1 Incyte Corporation $3,236.00 10/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577415
Principal investigator 1 GlaxoSmithKline, LLC. $4,610.00 10/01/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192158524
Principal investigator 1 Amgen Inc. $5,256.16 07/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646612
Principal investigator 1 Genentech, Inc. $15,806.00 06/18/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573039
Principal investigator 1 GlaxoSmithKline, LLC. $3,768.93 06/11/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192158520
Principal investigator 1 Genentech, Inc. $1,129.00 06/04/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573035
Principal investigator 1 GlaxoSmithKline, LLC. $13,136.00 06/02/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192158528
Principal investigator 1 Genentech, Inc. $56,450.00 05/14/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573051
Principal investigator 1 Genentech, Inc. $28,225.00 04/25/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573043
Principal investigator 1 Genentech, Inc. $2,258.00 04/11/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573047
Principal investigator 1 GlaxoSmithKline, LLC. $14,561.04 04/09/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192158537
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.20 04/02/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192158512
Principal investigator 1 Incyte Corporation $7,600.00 03/27/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577331
Principal investigator 1 GlaxoSmithKline, LLC. $5,372.77 02/19/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192158516
Principal investigator 1 Amgen Inc. $44,284.80 02/05/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246646604
Principal investigator 1 Genentech, Inc. $12,250.00 01/13/2025 Non-covered Recipient Entity
ANALYZED HEALTH CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211573030
Principal investigator 1 Incyte Corporation $8.40 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577337
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577343
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577350
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577355
Principal investigator 1 Incyte Corporation $25.63 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577361
Principal investigator 1 Incyte Corporation $6.99 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577367
Principal investigator 1 Incyte Corporation $23.30 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577373
Principal investigator 1 Incyte Corporation $14.04 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577379
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577385
Principal investigator 1 Incyte Corporation $11.65 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577391
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577397
Principal investigator 1 Incyte Corporation $279.90 01/09/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240577403
Principal investigator 1 Amgen Inc. $84,957.63 01/02/2025 Non-covered Recipient Entity
PIONEER CLINICAL RESEARCH NY
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246646608